MTPN and type 2 diabetes mellitus: Additionally, miR-375 was found to be high in serum and pancreatic beta-cells of patients with type 2 diabetes mellitus (T2DM), which directly decreases the gene expression and secretion of insulin through targeting phosphoinositide-dependent kinase-1 (PDK1) and myotrophin, respectively (45, 46).